0001140361-24-014226.txt : 20240319 0001140361-24-014226.hdr.sgml : 20240319 20240319214801 ACCESSION NUMBER: 0001140361-24-014226 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240318 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ELMS STEVE CENTRAL INDEX KEY: 0001250195 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 24766179 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 29TH FL CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 4 1 form4.xml FORM 4 X0508 4 2024-03-18 0001368514 ADMA BIOLOGICS, INC. ADMA 0001250195 ELMS STEVE 489 5TH AVENUE 10TH FLOOR NEW YORK NY 10017 true false Common Stock 2024-03-18 4 S 0 49887 6.01 D 2527500 I See footnote Common Stock 2024-03-19 4 S 0 411829 6.08 D 2115671 I See footnote Common Stock 76441 D These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.17. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Includes, as of the transaction date, (i) 24,040 restricted stock units ("RSUs") granted on February 26, 2024 and reported on this Form 4, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 52,401 shares of common stock owned by the reporting person. /s/ Steve Elms, by Brian Lenz as Attorney-in-fact 2024-03-19